Why is Mankind Pharma falling/rising?

As of 29-Aug, Mankind Pharma Ltd's stock price is currently at 2,473.00, reflecting a decrease of 2.05, or 0.08%. The stock has been on a downward trend, having lost 5.25% over the past week and 3.13% over the past month. It has also been declining for the last four consecutive days. The stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 56.72% compared to the 5-day average. Despite these challenges, the company boasts a high management efficiency with a return on equity (ROE) of 17.21%, a low debt-to-equity ratio, and healthy long-term growth in net sales and operating profit.
In the broader market context, Mankind Pharma's recent performance contrasts with the benchmark Sensex, which has declined by only 1.84% over the past week. While the stock has underperformed the benchmark significantly year-to-date, with a drop of 14.04% compared to the Sensex's gain of 2.14%, it has shown a slight positive return of 1.92% over the past year, while the Sensex has fallen by 2.83%. The high institutional holdings at 24.58% suggest that knowledgeable investors are backing the company, which may provide some stability despite the current price decline. Overall, the combination of recent poor performance, reduced trading activity, and the contrasting performance against the benchmark indicates a challenging environment for Mankind Pharma's stock.